Pulmonary Embolism Clinical Trial
Official title:
Risk Stratification for Patients Presenting With Acute Pulmonary Embolism (PE)
Hypothesis: Increases in CRP, trop T, and BNP values will correlate significantly with right
heart failure on echocardiogram and with mortality, ICU stay, hospital stay, and escalations
in care.
1. Evaluate whether CRP, trop T, and BNP correlate significantly with right heart failure
on echocardiogram.
2. Evaluate whether CRP, trop T, BNP, and echocardiogram correlate significantly with
clinical outcomes: mortality, ICU stay, hospital stay, and escalations in care.
3. Compare each test's correlation with clinical outcomes to the others, to determine
which test provides the best risk ratio.
4. Compare each trop T value's correlation with echo findings and clinical outcomes to
determine the optimal time to draw trop T levels on a patient presenting with acute PE.
5. These tests will not be used in an attempt to establish a diagnosis of PE.
Purpose: This study will help us to determine whether laboratory tests used to evaluate
cardiac function and blood flow (troponin T (trop T), C-reactive protein (CRP), and
brain-natriuretic peptide (BNP)) correlate with findings on echocardiogram and with
meaningful clinical outcomes when patients present with acute pulmonary embolism (PE). We
will be studying these tests for prognostic purposes only, in patients with an established
diagnosis of PE.
Research design: Prospective cohort study Methodology: Patients diagnosed with acute PE (see
exclusion and inclusion criteria below) will be offered enrollment in the study. Once
enrolled, he/she will then have a trans-thoracic echocardiogram (TTE) performed by a member
of the cardiology service who will not be aware of the patient's clinical status,
co-morbidities, or lab results (other than knowing that the patient has been diagnosed with
acute PE). The patient will then have trop T, CRP, and BNP levels drawn (or added to
laboratory tests that have already been drawn), which will be ordered by a member of the
research team. CRP and BNP will be drawn only once, while trop T levels will be drawn every
4 hours for the first 24 hours, and every 8 hours from 24 to 48 hours. The primary team
managing the patients will be privy to both the additional laboratory values ordered by the
research team and the results of the TTE.
Each patient will be followed for the remainder of their hospital stay by a member of the
research team. The following outcomes will be recorded: deaths, length of ICU stay, length
of hospital stay, and escalations in care (pressor support, cardiopulmonary resuscitation
(CPR), administration of thrombolytics, mechanical ventilation, ICU transfer).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |